Production of Remedial Proteins through Genetically Modified Bacteria

Recombinant DNA technology has created biological organisms with advanced genetic sequences and has been extensively used to express multiple genes for therapeutic purposes when expressed in a suitable host. Microbial systems such as prokaryotic bacteria has been successfully utilized as a heterologous systems showing high therapeutic potency for various human diseases. Bioengineered bacteria have been successfully utilized for producing therapeutic proteins, treating infectious diseases, and disease arise due to increasing resistance to antibiotics. Prominently  E. coli found to be the most widely used expression system for recombinant therapeutic protein production i.e. hormones, enzymes and antibodies. Besides  E. coli,  non-pathogenic lactic acid bacteria has also been considered as an excellent candidate for live mucosal vaccine. Likewise,  S. typhimurium has been deployed as attenuated type of vaccination as well as in treatment strategy of various cancers due to its ability of wide progression in tumors. The present article is a summarized view of the main achievements and current developments in the field of recombinant therapeutics using bacterial strains focusing on their usability in therapeutics and future potential.